(The following press release from Schroders was received by e-mail. The sender verified the statement.) Schroders notes with disappointment the quick rejection by the AstraZeneca Board of the latest offer from Pfizer and the decision of the Pfizer Board to draw a premature end to these negotiations by calling their latest proposal Final. As long term shareholders, we are strong believers in AstraZeneca and the potential for its innovative growth pipeline, however, given the increase in the offer we would encourage the AstraZeneca management to recommence their engagement with Pfizer, and subsequently their shareholders.
SCHRODERS URGES ASTRAZENECA TO RESTART TALKS WITH PFIZER